Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Camrelizumab |
Trade Name | |
Synonyms | SHR-1210|INCSHR-1210 |
Drug Descriptions |
Camrelizumab (SHR-1210) is an antibody that targets PD-1 (PDCD1) and inhibits binding of PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in activation of anti-tumor immune response and decreased tumor growth (PMID: 29358502, PMID: 32623573, PMID: 32581041). |
DrugClasses | Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83 |
CAS Registry Number | 1798286-48-2 |
NCIT ID | C123816 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Camrelizumab | Camrelizumab | 0 | 0 |
Camrelizumab + Cisplatin + Gemcitabine | Camrelizumab Cisplatin Gemcitabine | 0 | 0 |
Camrelizumab + Lenvatinib | Camrelizumab Lenvatinib | 0 | 0 |
Camrelizumab + Rivoceranib | Camrelizumab Rivoceranib | 0 | 0 |
Camrelizumab + Rivoceranib + SHR9146 | Camrelizumab Rivoceranib SHR9146 | 0 | 0 |
Camrelizumab + SHR9146 | Camrelizumab SHR9146 | 0 | 0 |